Answers are grounded in this paper and cite their sources.
Introduction Factor XI (FXI) deficiency is a rare autosomal recessive bleeding disorder that causes coagulopathy. While the implications of general coagulation dysfunction during pregnancy are recognized, reports on severe compound heterozygous FXI deficiency complicated by a uterus didelphys and a twin pregnancy are exceedingly rare. Case Presentation We herein present a 29-year-old woman with a monochorionic diamniotic twin pregnancy and a uterus didelphys who was admitted at 32 weeks and 3 days of gestation due to a prolonged APTT. Despite lacking prior clinical hemorrhagic symptoms, she was diagnosed with severe FXI deficiency driven by a compound heterozygous mutation in the F11 gene. Managed by a multidisciplinary team (MDT), she underwent an emergency cesarean section under general anesthesia at 36 weeks and 1 day, successfully delivering both infants. Her perioperative coagulation profile was optimized via intravenous fresh frozen plasma that targeted the clinical hemostasis rather than the absolute laboratory values. Diligent monitoring confirmed no abnormal postpartum hemorrhage (PPH), and the woman remained hemodynamically stable. Both premature infants subsequently developed necrotizing enterocolitis but fully recovered following comprehensive treatment. Conclusion The primary hazard associated with severe FXI deficiency is PPH, and there is often a lack of significant correlation between the severity of clinical bleeding and laboratory values. Therefore, the prenatal assessment and peripartum management of this rare coagulopathy pose significant challenges. Prompt MDT recognition, individualized intervention, and ongoing care for pregnant individuals affected by inherited bleeding disorders are thus crucial for optimizing maternal and neonatal health outcomes.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: